Abciximab
Icatibant may increase the anticoagulant activities of Abciximab.
Acebutolol
Icatibant may decrease the antihypertensive activities of Acebutolol.
Aceclofenac
The risk or severity of adverse effects can be increased when Icatibant is combined with Aceclofenac.
Advertisement
Acemetacin
The risk or severity of adverse effects can be increased when Icatibant is combined with Acemetacin.
Acenocoumarol
Icatibant may increase the anticoagulant activities of Acenocoumarol.
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Icatibant.
Advertisement
Aclarubicin
Icatibant may decrease the excretion rate of Aclarubicin which could result in a higher serum level.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Icatibant.
Alclometasone
The risk or severity of adverse effects can be increased when Icatibant is combined with Alclometasone.
Advertisement
Aldosterone
The risk or severity of adverse effects can be increased when Icatibant is combined with Aldosterone.
Alendronate
The risk or severity of adverse effects can be increased when Icatibant is combined with Alendronic acid.
Alendronic acid
The risk or severity of adverse effects can be increased when Icatibant is combined with Alendronic acid.
Aliskiren
Icatibant may decrease the antihypertensive activities of Aliskiren.
Alminoprofen
The risk or severity of adverse effects can be increased when Icatibant is combined with Alminoprofen.
Alprenolol
Icatibant may decrease the antihypertensive activities of Alprenolol.
Alprostadil
The therapeutic efficacy of Alprostadil can be decreased when used in combination with Icatibant.
Amcinonide
The risk or severity of adverse effects can be increased when Icatibant is combined with Amcinonide.
Amikacin
Icatibant may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride
Icatibant may decrease the antihypertensive activities of Amiloride.
Ancrod
Icatibant may increase the anticoagulant activities of Ancrod.
Androstenedione
The risk or severity of adverse effects can be increased when Icatibant is combined with Androstenedione.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Icatibant.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Icatibant is combined with Anthrax immune globulin human.
Antipyrine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Icatibant.
Antithrombin III
Icatibant may increase the anticoagulant activities of Antithrombin III human.
Antithrombin III, Human
Icatibant may increase the anticoagulant activities of Antithrombin III human.
Apazone
The risk or severity of adverse effects can be increased when Icatibant is combined with Azapropazone.
Apixaban
Icatibant may increase the anticoagulant activities of Apixaban.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Icatibant.
Arbekacin
Icatibant may decrease the excretion rate of Arbekacin which could result in a higher serum level.
Ardeparin
Icatibant may increase the anticoagulant activities of Ardeparin.
Argatroban
Icatibant may increase the anticoagulant activities of Argatroban.
Argatroban Anhydrous
Icatibant may increase the anticoagulant activities of Argatroban.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Icatibant.
Atenolol
Icatibant may decrease the antihypertensive activities of Atenolol.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Icatibant.
azficel-T
The risk or severity of adverse effects can be increased when Icatibant is combined with Azficel-T.
Azilsartan
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Icatibant.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Icatibant.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Icatibant.
Azosemide
The therapeutic efficacy of Azosemide can be decreased when used in combination with Icatibant.
Balsalazide
Icatibant may increase the nephrotoxic activities of Balsalazide.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Icatibant.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Icatibant is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Icatibant is combined with Bacillus calmette-guerin substrain tice live antigen.
Becaplermin
Icatibant may increase the anticoagulant activities of Becaplermin.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Icatibant is combined with Beclomethasone dipropionate.
Benazepril
Icatibant may decrease the antihypertensive activities of Benazepril.
Bendroflumethiazide
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Icatibant.
Benzydamine
The risk or severity of adverse effects can be increased when Icatibant is combined with Benzydamine.
Betamethasone
The risk or severity of adverse effects can be increased when Icatibant is combined with Betamethasone.
Betaxolol
Icatibant may decrease the antihypertensive activities of Betaxolol.
Betrixaban
The risk or severity of bleeding can be increased when Betrixaban is combined with Icatibant.
Bimatoprost
The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Icatibant.
Bisoprolol
Icatibant may decrease the antihypertensive activities of Bisoprolol.
Bivalirudin
Icatibant may increase the anticoagulant activities of Bivalirudin.
Bopindolol
Icatibant may decrease the antihypertensive activities of Bopindolol.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Icatibant.
Budesonide
The risk or severity of adverse effects can be increased when Icatibant is combined with Budesonide.
Bufexamac
The risk or severity of adverse effects can be increased when Icatibant is combined with Bufexamac.
Bumetanide
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Icatibant.
Bupranolol
Icatibant may decrease the antihypertensive activities of Bupranolol.
Candesartan
The risk or severity of adverse effects can be increased when Candesartan is combined with Icatibant.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Icatibant.
Captopril
Icatibant may decrease the antihypertensive activities of Captopril.
Carboprost
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Icatibant.
Carboprost Tromethamine
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Icatibant.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Icatibant.
Carteolol
Icatibant may decrease the antihypertensive activities of Carteolol.
Carvedilol
Icatibant may decrease the antihypertensive activities of Carvedilol.
Celecoxib
The risk or severity of adverse effects can be increased when Icatibant is combined with Celecoxib.
Celiprolol
Icatibant may decrease the antihypertensive activities of Celiprolol.
Certoparin
Icatibant may increase the anticoagulant activities of Certoparin.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Icatibant.
Chlorothiazide
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Icatibant.
Chlorthalidone
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Icatibant.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Icatibant resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Icatibant.
Ciclesonide
The risk or severity of adverse effects can be increased when Icatibant is combined with Ciclesonide.
Cilazapril
Icatibant may decrease the antihypertensive activities of Cilazapril.
Cinoxacin
Icatibant may increase the neuroexcitatory activities of Cinoxacin.
Citric Acid
Icatibant may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Icatibant may increase the anticoagulant activities of Citric Acid.
Clobetasol
The risk or severity of adverse effects can be increased when Icatibant is combined with Clobetasol.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Icatibant is combined with Clobetasol propionate.
Clobetasone
The risk or severity of adverse effects can be increased when Icatibant is combined with Clobetasone.
Clocortolone
The risk or severity of adverse effects can be increased when Icatibant is combined with Clocortolone.
Clodronic Acid
The risk or severity of adverse effects can be increased when Icatibant is combined with Clodronic Acid.
Clonixin
The risk or severity of adverse effects can be increased when Icatibant is combined with Clonixin.
Colesevelam
Colesevelam can cause a decrease in the absorption of Icatibant resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Icatibant resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Icatibant is combined with Cortisone acetate.
Curcumin
The risk or severity of adverse effects can be increased when Icatibant is combined with Curcumin.
Cyclopenthiazide
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Icatibant.
Cyclosporine
Icatibant may increase the nephrotoxic activities of Cyclosporine.
Dabigatran Etexilate
Icatibant may increase the anticoagulant activities of Dabigatran etexilate.
Dalteparin
Icatibant may increase the anticoagulant activities of Dalteparin.
Danaparoid
Icatibant may increase the anticoagulant activities of Danaparoid.
Daunorubicin
Icatibant may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Deferasirox
The risk or severity of adverse effects can be increased when Icatibant is combined with Deferasirox.
Deflazacort
The risk or severity of adverse effects can be increased when Icatibant is combined with Deflazacort.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Icatibant.
Desirudin
Icatibant may increase the anticoagulant activities of Desirudin.
Desmopressin
The risk or severity of adverse effects can be increased when Icatibant is combined with Desmopressin.
Desonide
The risk or severity of adverse effects can be increased when Icatibant is combined with Desonide.
Desoximetasone
The risk or severity of adverse effects can be increased when Icatibant is combined with Desoximetasone.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Icatibant is combined with Desoxycorticosterone acetate.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Icatibant is combined with Desoxycorticosterone Pivalate.
Dexamethasone
The risk or severity of adverse effects can be increased when Icatibant is combined with Dexamethasone.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Icatibant.
Dextran
Icatibant may increase the anticoagulant activities of Dextran.
Dextran 40
Icatibant may increase the anticoagulant activities of Dextran 40.
Dextran 70
Icatibant may increase the anticoagulant activities of Dextran 70.
Dextran 75
Icatibant may increase the anticoagulant activities of Dextran 75.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Icatibant.
Dicumarol
Icatibant may increase the anticoagulant activities of Dicoumarol.
Diflorasone
The risk or severity of adverse effects can be increased when Icatibant is combined with Diflorasone.
Diflucortolone
The risk or severity of adverse effects can be increased when Icatibant is combined with Difluocortolone.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Icatibant.
Difluprednate
The risk or severity of adverse effects can be increased when Icatibant is combined with Difluprednate.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Icatibant.
Dihydrostreptomycin
Icatibant may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.
Dinoprost
The therapeutic efficacy of Dinoprost can be decreased when used in combination with Icatibant.
Dinoprost Tromethamine
The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Icatibant.
Dinoprostone
The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Icatibant.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Icatibant.
Doxorubicin
Icatibant may decrease the excretion rate of Doxorubicin which could result in a higher serum level.
Doxorubicin Hydrochloride
Icatibant may decrease the excretion rate of Doxorubicin which could result in a higher serum level.
Drospirenone
Icatibant may increase the hyperkalemic activities of Drospirenone.
Droxicam
The risk or severity of adverse effects can be increased when Icatibant is combined with Droxicam.
Edetic Acid
Icatibant may increase the anticoagulant activities of Edetic Acid.
Edoxaban
Icatibant may increase the anticoagulant activities of Edoxaban.
Enalapril
Icatibant may decrease the antihypertensive activities of Enalapril.
Enalaprilat
Icatibant may decrease the antihypertensive activities of Enalaprilat.
Enalaprilat Anhydrous
Icatibant may decrease the antihypertensive activities of Enalaprilat.
Enoxacin
Icatibant may increase the neuroexcitatory activities of Enoxacin.
Enoxaparin
Icatibant may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Icatibant may increase the anticoagulant activities of Enoxaparin.
Epirubicin
Icatibant may decrease the excretion rate of Epirubicin which could result in a higher serum level.
Eplerenone
Icatibant may decrease the antihypertensive activities of Eplerenone.
Epoprostenol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Icatibant.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Icatibant.
Esmolol
Icatibant may decrease the antihypertensive activities of Esmolol.
Estrone
The risk or severity of adverse effects can be increased when Icatibant is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Icatibant.
Ethacrynate
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Icatibant.
Ethacrynic Acid
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Icatibant.
Ethylenediaminetetraacetate
Icatibant may increase the anticoagulant activities of Edetic Acid.
Etidronate
The risk or severity of adverse effects can be increased when Icatibant is combined with Etidronic acid.
Etidronic Acid
The risk or severity of adverse effects can be increased when Icatibant is combined with Etidronic acid.
Etodolac
The risk or severity of adverse effects can be increased when Icatibant is combined with Etodolac.
Etofenamate
The risk or severity of adverse effects can be increased when Icatibant is combined with Etofenamate.
Etoricoxib
The risk or severity of adverse effects can be increased when Icatibant is combined with Etoricoxib.
Evening primrose oil
The risk or severity of adverse effects can be increased when Icatibant is combined with Evening primrose oil.
Felbinac
The risk or severity of adverse effects can be increased when Icatibant is combined with Felbinac.
Fenbufen
The risk or severity of adverse effects can be increased when Icatibant is combined with Fenbufen.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Icatibant.
Ferulic Acid
Icatibant may increase the anticoagulant activities of Ferulic acid.
Fingolimod
Icatibant may increase the immunosuppressive activities of Fingolimod.
Fleroxacin
Icatibant may increase the neuroexcitatory activities of Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Icatibant.
Fludrocortisone
The risk or severity of adverse effects can be increased when Icatibant is combined with Fludrocortisone.
Fluindione
Icatibant may increase the anticoagulant activities of Fluindione.
Flumequine
Icatibant may increase the neuroexcitatory activities of Flumequine.
Flumethasone
The risk or severity of adverse effects can be increased when Icatibant is combined with Flumethasone.
Flunisolide
The risk or severity of adverse effects can be increased when Icatibant is combined with Flunisolide.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Icatibant is combined with Flunisolide.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Icatibant is combined with Fluocinolone Acetonide.
Fluocinonide
The risk or severity of adverse effects can be increased when Icatibant is combined with Fluocinonide.
Fluocortolone
The risk or severity of adverse effects can be increased when Icatibant is combined with Fluocortolone.
Fluorometholone
The risk or severity of adverse effects can be increased when Icatibant is combined with Fluorometholone.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Icatibant is combined with Fluprednidene.
Fluprednisolone
The risk or severity of adverse effects can be increased when Icatibant is combined with Fluprednisolone.
Flurandrenolide
The risk or severity of adverse effects can be increased when Icatibant is combined with Flurandrenolide.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Icatibant.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Icatibant is combined with Fluticasone furoate.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Icatibant is combined with Fluticasone propionate.
Folate
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Icatibant.
Folic Acid
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Icatibant.
Fondaparinux
Icatibant may increase the anticoagulant activities of Fondaparinux.
Fondaparinux sodium
Icatibant may increase the anticoagulant activities of Fondaparinux sodium.
Formestane
The risk or severity of adverse effects can be increased when Icatibant is combined with Formestane.
Fosinopril
Icatibant may decrease the antihypertensive activities of Fosinopril.
Framycetin
Icatibant may decrease the excretion rate of Framycetin which could result in a higher serum level.
Furosemide
The therapeutic efficacy of Furosemide can be decreased when used in combination with Icatibant.
Gatifloxacin
Icatibant may increase the neuroexcitatory activities of Gatifloxacin.
Gatifloxacin Anhydrous
Icatibant may increase the neuroexcitatory activities of Gatifloxacin.
Gemeprost
The therapeutic efficacy of Gemeprost can be decreased when used in combination with Icatibant.
Gemifloxacin
Icatibant may increase the neuroexcitatory activities of Gemifloxacin.
Gemifloxacin Mesylate
Icatibant may increase the neuroexcitatory activities of Gemifloxacin.
Gentamicin
Icatibant may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Grepafloxacin
Icatibant may increase the neuroexcitatory activities of Grepafloxacin.
Halcinonide
The risk or severity of adverse effects can be increased when Icatibant is combined with Halcinonide.
Halobetasol
The risk or severity of adverse effects can be increased when Icatibant is combined with Ulobetasol.
Haloperidol
The risk or severity of adverse effects can be increased when Icatibant is combined with Haloperidol.
Heparin
Icatibant may increase the anticoagulant activities of Heparin.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Icatibant is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Icatibant is combined with Hepatitis B Vaccine (Recombinant).
Hydralazine
Icatibant may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Icatibant.
Hydrocortisone
The risk or severity of adverse effects can be increased when Icatibant is combined with Hydrocortisone.
Hydroflumethiazide
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Icatibant.
Ibandronate
The risk or severity of adverse effects can be increased when Icatibant is combined with Ibandronate.
Ibandronic Acid
The risk or severity of adverse effects can be increased when Icatibant is combined with Ibandronate.
Ibuprofen
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Icatibant.
Idarubicin
Icatibant may decrease the excretion rate of Idarubicin which could result in a higher serum level.
Iloprost
The therapeutic efficacy of Iloprost can be decreased when used in combination with Icatibant.
Imidapril
Icatibant may decrease the antihypertensive activities of Imidapril.
Indapamide
The therapeutic efficacy of Indapamide can be decreased when used in combination with Icatibant.
Indobufen
The risk or severity of adverse effects can be increased when Icatibant is combined with Indobufen.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Icatibant.
Irbesartan
The risk or severity of adverse effects can be increased when Irbesartan is combined with Icatibant.
Kanamycin
Icatibant may decrease the excretion rate of Kanamycin which could result in a higher serum level.
kanamycin A
Icatibant may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Kebuzone
The risk or severity of adverse effects can be increased when Icatibant is combined with Kebuzone.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Icatibant.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Icatibant.
Labetalol
Icatibant may decrease the antihypertensive activities of Labetalol.
Latanoprost
The therapeutic efficacy of Latanoprost can be decreased when used in combination with Icatibant.
Latanoprostene Bunod
The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Icatibant.
Leflunomide
The risk or severity of adverse effects can be increased when Icatibant is combined with Leflunomide.
Lepirudin
Icatibant may increase the anticoagulant activities of Lepirudin.
Levobunolol
Icatibant may decrease the antihypertensive activities of Levobunolol.
Levofloxacin
Icatibant may increase the neuroexcitatory activities of Levofloxacin.
Levofloxacin Anhydrous
Icatibant may increase the neuroexcitatory activities of Levofloxacin.
Limonene, (+)-
The risk or severity of adverse effects can be increased when Icatibant is combined with (4R)-limonene.
Lisinopril
Icatibant may decrease the antihypertensive activities of Lisinopril.
Lisinopril Anhydrous
Icatibant may decrease the antihypertensive activities of Lisinopril.
Lithium
The serum concentration of Lithium can be increased when it is combined with Icatibant.
Lithium Cation
The serum concentration of Lithium can be increased when it is combined with Icatibant.
Lornoxicam
The risk or severity of adverse effects can be increased when Icatibant is combined with Lornoxicam.
Losartan
The risk or severity of adverse effects can be increased when Losartan is combined with Icatibant.
Loteprednol
The risk or severity of adverse effects can be increased when Icatibant is combined with Loteprednol.
Loxoprofen
The risk or severity of adverse effects can be increased when Icatibant is combined with Loxoprofen.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Icatibant.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Icatibant.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Icatibant.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Icatibant.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Icatibant.
Medronate
The risk or severity of adverse effects can be increased when Icatibant is combined with Technetium Tc-99m medronate.
Medrysone
The risk or severity of adverse effects can be increased when Icatibant is combined with Medrysone.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Icatibant.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Icatibant.
Mesalamine
Icatibant may increase the nephrotoxic activities of Mesalazine.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Icatibant.
Methyclothiazide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Icatibant.
Methylprednisolone
The risk or severity of adverse effects can be increased when Icatibant is combined with Methylprednisolone.
Metipranolol
Icatibant may decrease the antihypertensive activities of Metipranolol.
Metolazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Icatibant.
Metoprolol
Icatibant may decrease the antihypertensive activities of Metoprolol.
Metrizamide
Icatibant may decrease the excretion rate of Metrizamide which could result in a higher serum level.
Misoprostol
The therapeutic efficacy of Misoprostol can be decreased when used in combination with Icatibant.
Moexipril
Icatibant may decrease the antihypertensive activities of Moexipril.
Mometasone
The risk or severity of adverse effects can be increased when Icatibant is combined with Mometasone.
Morniflumate
The risk or severity of adverse effects can be increased when Morniflumate is combined with Icatibant.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Icatibant.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Icatibant.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Icatibant.
Nabumetone
The risk or severity of adverse effects can be increased when Icatibant is combined with Nabumetone.
Nadolol
Icatibant may decrease the antihypertensive activities of Nadolol.
Nadroparin
Icatibant may increase the anticoagulant activities of Nadroparin.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Icatibant.
Nalidixic Acid
Icatibant may increase the neuroexcitatory activities of Nalidixic Acid.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Icatibant.
Natalizumab
The risk or severity of adverse effects can be increased when Icatibant is combined with Natalizumab.
Nebivolol
Icatibant may decrease the antihypertensive activities of Nebivolol.
Neomycin
Icatibant may decrease the excretion rate of Neomycin which could result in a higher serum level.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Icatibant.
Netilmicin
Icatibant may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Niflumic Acid
The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Icatibant.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Icatibant.
Norfloxacin
Icatibant may increase the neuroexcitatory activities of Norfloxacin.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Icatibant.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Icatibant is combined with Evening primrose oil.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Icatibant.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Icatibant.
Olsalazine
Icatibant may increase the nephrotoxic activities of Olsalazine.
Omacetaxine Mepesuccinate
The risk or severity of bleeding can be increased when Icatibant is combined with Omacetaxine mepesuccinate.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Icatibant.
Oxprenolol
Icatibant may decrease the antihypertensive activities of Oxprenolol.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Icatibant.
Pamidronate
The risk or severity of adverse effects can be increased when Icatibant is combined with Pamidronate.
Pamidronic Acid
The risk or severity of adverse effects can be increased when Icatibant is combined with Pamidronate.
Paramethasone
The risk or severity of adverse effects can be increased when Icatibant is combined with Paramethasone.
Parecoxib
The risk or severity of adverse effects can be increased when Icatibant is combined with Parecoxib.
Paromomycin
Icatibant may decrease the excretion rate of Paromomycin which could result in a higher serum level.
Parthenolide
The risk or severity of adverse effects can be increased when Icatibant is combined with Parthenolide.
Pefloxacin
Icatibant may increase the neuroexcitatory activities of Pefloxacin.
Penbutolol
Icatibant may decrease the antihypertensive activities of Penbutolol.
Pentaerythritol Tetranitrate
Icatibant may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentosan Polysulfate
Icatibant may increase the anticoagulant activities of Pentosan Polysulfate.
Perindopril
Icatibant may decrease the antihypertensive activities of Perindopril.
Phenindione
Icatibant may increase the anticoagulant activities of Phenindione.
Phenprocoumon
Icatibant may increase the anticoagulant activities of Phenprocoumon.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Icatibant.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Icatibant.
Pindolol
Icatibant may decrease the antihypertensive activities of Pindolol.
Pirarubicin
Icatibant may decrease the excretion rate of Pirarubicin which could result in a higher serum level.
Piretanide
The therapeutic efficacy of Piretanide can be decreased when used in combination with Icatibant.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Icatibant.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Icatibant.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Icatibant.
Plicamycin
Icatibant may decrease the excretion rate of Plicamycin which could result in a higher serum level.
Polythiazide
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Icatibant.
Practolol
Icatibant may decrease the antihypertensive activities of Practolol.
Pralatrexate
The serum concentration of Pralatrexate can be increased when it is combined with Icatibant.
Prasterone
The risk or severity of adverse effects can be increased when Icatibant is combined with Prasterone.
Prednicarbate
The risk or severity of adverse effects can be increased when Icatibant is combined with Prednicarbate.
Prednisolone
The risk or severity of adverse effects can be increased when Icatibant is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Icatibant is combined with Prednisone.
Pregnenolone
The risk or severity of adverse effects can be increased when Icatibant is combined with Pregnenolone.
Probenecid
The serum concentration of Icatibant can be increased when it is combined with Probenecid.
Propranolol
Icatibant may decrease the antihypertensive activities of Propranolol.
protein C, human
Icatibant may increase the anticoagulant activities of Protein C.
protein S, human
Icatibant may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Icatibant may increase the anticoagulant activities of Protocatechualdehyde.
Quinapril
Icatibant may decrease the antihypertensive activities of Quinapril.
Quinethazone
The therapeutic efficacy of Quinethazone can be decreased when used in combination with Icatibant.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Icatibant is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Icatibant is combined with Rabies virus inactivated antigen, A.
Ramipril
Icatibant may decrease the antihypertensive activities of Ramipril.
Rescinnamine
Icatibant may decrease the antihypertensive activities of Rescinnamine.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Icatibant.
Reviparin
Icatibant may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Icatibant may increase the anticoagulant activities of Reviparin.
Rimexolone
The risk or severity of adverse effects can be increased when Icatibant is combined with Rimexolone.
Risedronate
The risk or severity of adverse effects can be increased when Icatibant is combined with Risedronate.
Risedronic Acid
The risk or severity of adverse effects can be increased when Icatibant is combined with Risedronate.
Rivaroxaban
Icatibant may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib
The risk or severity of adverse effects can be increased when Icatibant is combined with Rofecoxib.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Icatibant.
Rosoxacin
Icatibant may increase the neuroexcitatory activities of Rosoxacin.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Icatibant is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Icatibant is combined with Rubella virus vaccine.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Icatibant.
Salicylamide
The risk or severity of adverse effects can be increased when Icatibant is combined with Salicylamide.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Icatibant.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Icatibant is combined with Salmonella typhi ty21a live antigen.
Salsalate
The risk or severity of adverse effects can be increased when Salsalate is combined with Icatibant.
Saralasin
The risk or severity of adverse effects can be increased when Saralasin is combined with Icatibant.
Sarilumab
Sarilumab may increase the immunosuppressive activities of Icatibant.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Icatibant is combined with Serrapeptase.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Icatibant.
Sisomicin
Icatibant may decrease the excretion rate of Sisomicin which could result in a higher serum level.
Sodium Phosphate
Sodium phosphate may increase the nephrotoxic activities of Icatibant.
Sodium Phosphate, Monobasic
Sodium phosphate may increase the nephrotoxic activities of Icatibant.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Sodium phosphate may increase the nephrotoxic activities of Icatibant.
Sotalol
Icatibant may decrease the antihypertensive activities of Sotalol.
Sparfloxacin
Icatibant may increase the neuroexcitatory activities of Sparfloxacin.
Spectinomycin
Icatibant may decrease the excretion rate of Spectinomycin which could result in a higher serum level.
Spirapril
Icatibant may decrease the antihypertensive activities of Spirapril.
Spironolactone
Icatibant may decrease the antihypertensive activities of Spironolactone.
Streptomycin
Icatibant may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Streptozocin
Icatibant may decrease the excretion rate of Streptozocin which could result in a higher serum level.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Icatibant.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Icatibant.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Icatibant.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Icatibant.
Tafluprost
The therapeutic efficacy of Tafluprost can be decreased when used in combination with Icatibant.
Talinolol
Icatibant may decrease the antihypertensive activities of Talinolol.
Talniflumate
The risk or severity of adverse effects can be increased when Talniflumate is combined with Icatibant.
Technetium Tc 99m Medronate
The risk or severity of adverse effects can be increased when Icatibant is combined with Technetium Tc-99m medronate.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Icatibant.
Temafloxacin
Icatibant may increase the neuroexcitatory activities of Temafloxacin.
Tenofovir Disoproxil
The risk or severity of adverse effects can be increased when Icatibant is combined with Tenofovir disoproxil.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Icatibant.
Teriflunomide
The risk or severity of adverse effects can be increased when Icatibant is combined with Teriflunomide.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Icatibant is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Icatibant.
Tiludronate
The risk or severity of adverse effects can be increased when Icatibant is combined with Tiludronic acid.
Tiludronic Acid
The risk or severity of adverse effects can be increased when Icatibant is combined with Tiludronic acid.
Timolol
Icatibant may decrease the antihypertensive activities of Timolol.
Timolol Anhydrous
Icatibant may decrease the antihypertensive activities of Timolol.
Tixocortol
The risk or severity of adverse effects can be increased when Icatibant is combined with Tixocortol.
Tobramycin
Icatibant may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tofacitinib
Icatibant may increase the immunosuppressive activities of Tofacitinib.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Icatibant is combined with Tolfenamic Acid.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Icatibant.
Torsemide
The therapeutic efficacy of Torasemide can be decreased when used in combination with Icatibant.
Trandolapril
Icatibant may decrease the antihypertensive activities of Trandolapril.
Tranilast
The risk or severity of adverse effects can be increased when Icatibant is combined with Tranilast.
Trastuzumab
Trastuzumab may increase the neutropenic activities of Icatibant.
Travoprost
The therapeutic efficacy of Travoprost can be decreased when used in combination with Icatibant.
Treprostinil
The risk or severity of adverse effects can be increased when Treprostinil is combined with Icatibant.
Triamcinolone
The risk or severity of adverse effects can be increased when Icatibant is combined with Triamcinolone.
Triamterene
Icatibant may decrease the antihypertensive activities of Triamterene.
Trichlormethiazide
The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Icatibant.
Trovafloxacin
Icatibant may increase the neuroexcitatory activities of Trovafloxacin.
Troxerutin
Icatibant may increase the anticoagulant activities of Troxerutin.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Icatibant is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Icatibant is combined with Salmonella typhi ty2 vi polysaccharide antigen.
UNOPROSTONE
The therapeutic efficacy of Unoprostone can be decreased when used in combination with Icatibant.
Valdecoxib
The risk or severity of adverse effects can be increased when Icatibant is combined with Valdecoxib.
Valrubicin
Icatibant may decrease the excretion rate of Valrubicin which could result in a higher serum level.
Valsartan
The risk or severity of adverse effects can be increased when Valsartan is combined with Icatibant.
Vancomycin
The serum concentration of Vancomycin can be increased when it is combined with Icatibant.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Icatibant is combined with Varicella Zoster Vaccine (Live/Attenuated).
Warfarin
Icatibant may increase the anticoagulant activities of Warfarin.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Icatibant is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Icatibant is combined with Yellow Fever Vaccine.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Icatibant.
Zofenopril
Icatibant may decrease the antihypertensive activities of Zofenopril.
Zoledronic Acid
The risk or severity of adverse effects can be increased when Icatibant is combined with Zoledronic acid.
Zoledronic Acid Anhydrous
The risk or severity of adverse effects can be increased when Icatibant is combined with Zoledronic acid.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Icatibant.
